Impact of ۱۸F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative ۱۳۱I whole body scan and elevated serum thyroglobulin
Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 414
This Paper With 8 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JNMB-10-1_003
تاریخ نمایه سازی: 11 دی 1400
Abstract:
Objective(s): ۱۸F-FDG PET/CT is increasingly performed in patients with differentiated thyroid cancer. The aim of this study was to assess the clinical impact of ۱۸FFDG PET/CT on the management of patients with differentiated thyroid carcinoma who had elevated serum thyroglobulin (Tg) and negative ۱۳۱I whole body scan (WBS) .Methods: ۶۷ patients with differentiated thyroid carcinoma were included in this study. The findings of ۱۸F-FDG PET/CT imaging were compared with histopathology, follow up imaging, or clinical follow-up results. The diagnostic accuracy of ۱۸F-FDG PET/CT was evaluated for the entire patient group and for those patients with stimulated serum thyroglobulin levels of less than ۵, ۵–۱۰, and more than ۱۰ pmol/L as well as for local recurrences and metastases sites. The impact of ۱۸F-FDG PET/CT on therapeutic management was also evaluated.Results: ۳۰/۶۷ patients had positive findings on ۱۸F-FDG PET/CT; ۲۸ were truepositive and ۲ were false-positive. ۱۸F-FDG PET/CT results were true-negative in۳۶ patients and false-negative in ۱ patient. The overall sensitivity, specificity, accuracy, PPV and NPV of ۱۸F-FDG PET/CT were, ۹۶.۵%, ۹۴.۵%, ۹۵.۵%, ۹۳.۳%, and ۹۷.۲% respectively. Positive ۱۸F-FDG PET/CT findings were directly correlated with stimulated serum thyroglobulin levels, ۷.۱% had Tg between ۵–۱۰, and ۹۲.۹% had Tg greater than ۱۰ pmol/L. ۱۸F-FDG PET/CT had a high or moderate impact on treatment management in ۲۸ (۴۱.۸%) of patients.Conclusion: ۱۸F-FDG PET/CT is able to improve diagnostic accuracy and have management impact in a therapeutically relevant way in patients with differentiated thyroid carcinoma who present with rising thyroglobulin level, negative ۱۳۱I WBS, and clinical suspicion of recurrent disease.
Keywords:
Authors
Raef Boktor
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
Sze Ting Lee
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
Salvatore Berlangieri
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
Andrew Scott
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :